Sheryl Stevenson

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and patient experience.

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear Infirmary of Mount Sinai offers advanced options for every stage of life.

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance on glasses and contacts.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.

Investigators were surprised by the outcome of a comparison between the Eyhance and enVista IOLs in low-light conditions.

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.

Ayres shares insights on using a trocar-free, 27-gauge vitrector to improve surgeon comfort and patient safety in anterior vitrectomy

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on Ophthalmic Innovation is reshaping the field, streamlining outdated processes, and advancing patient-centered solutions worldwide.

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.

CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience

The first SightLine meeting, held pre-ASCRS, reveals insights on physician-industry relationships, mentorship opportunities, and the practical applications of AI in healthcare.

Outcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.

A machine learning model using treated astigmatism and other nuanced inputs can significantly improve the accuracy and personalization of arcuate keratotomy planning

The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.

Shehzad Batliwala, DO, known to his patients as Dr. Shehz, appeared on the ASCRS Foundation Symposium, where he discussed performing refractive surgery in low-resource, high-risk areas.